full comment requir non-u analyst conflict disclosur
pleas click link
mylan/biocon biosimilar pegfilgrastim fulphila approv fda pt
strengthen ecosystem takeaway wwdc
result increas confid earn power
result start bang
showcas outsourc water oppti analyst meet takeaway
forc natur increas pt
road manag
kkr share purchas repres attract use capit impact
updat investor meet addit detail reward/risk still
take forward-ii avastin mirv combo appear benefit durat
virginia medicaid expect bring dual benefit lpnt
take cemiplimab cscc data compel competit profil beyond unclear
take adcetri continu shine hl sub-group post-hoc analys
topacio tnbc updat remain confound tsro consid develop plan
preview cheat sheet
methanol price continu hold strong
price prior day market close estimate unless otherwis note
dell-emc print storag gain
med-tech takeaway
 of daili summari
oil strategi dissect
compon wti-brent
remain bullish rental
impact stx
lldpe lower pe outlook flat near-term
find research
insight www rbcinsightresearch com global research destin web contact capit market sale
repres access global research site use ipad app research
valu usd unless otherwis note
valu usd unless otherwis note
mylan/biocon biosimilar pegfilgrastim fulphila approv fda pt
expect fulphila approv pend biosimilar approv
creat signific headwind neulasta sale
today market close mylan/biocon announc biosimilar
neulasta pegfilgrastim-jmbd brand name fulphila approv
fda use patient nonmyeloid cancer receiv myelosuppress
chemotherapi reduc durat febril neutropenia decreas
chanc infect see randal stanicki note fulphila
first biosimilar version neulasta approv fda usa
plan commerci launch fulphila come week
seen signific uptak neulasta onpro injector sinc launch
growth neulasta usa come
onpro potenti protect initi biosimilar entri howev
anticip weak share given sever preced neulasta biosimilar
crl creat question surround today approv revis
neulasta estim slightli downward result pt reduct
strengthen ecosystem takeaway wwdc
attend keynot wwdc confer today outlin
need attend wwdc note
announc big/splashi focus small critic chang
strengthen ecosystem long term receiv crucial
upgrad close gap vs competit privaci
improv digit well heart updat year compani
also announc next version ar kit highlight continu focu
potenti technolog net/net strengthen ecosystem
see sever lever could convert low singl digit unit/sal growth
mid-teen ep growth gross margin upsid cost down nand
outperform adjust price target
result increas confid earn power
earn solid comp margin expans notabl even
compar overal healthi result across retail landscap quarter believ
conserv guidanc coupl lt potenti market share
gain margin catch-up off-pric peer pose compel path sustain
mid high-teen ep growth next year reiter op rais
pt
updat thought estim post earn
valu usd unless otherwis note
valu usd unless otherwis note
result start bang
coupa start blow-out quarter across metric enthus
continu market partner accept solid execut across
renew new acv anoth quarter net dollar retent
new spend manag ad quarter reiter outperform pt
beat across metric especi bill vs
free cash-flow vs driven better-than-expect new
acv renew profession servic note quarter
reacceler subscript revenu y/i adjust fact
adjust bill growth day quarter would
target trend
enthus continu market partner accept solid
execut anoth quarter net dollar retent new spend
manag ad quarter revis estim move pt
reiter outperform
showcas outsourc water oppti analyst meet takeaway
outperform-r evoqua host well-attend analyst meet outsid
boston featur strateg updat leadership team manufactur
facil tour visit outsourc water custom schneider electr
evoqua activ prepar nation roll-out highli differenti
one outsourc initi continu big fan evoqua busi
model execut capabl
valu usd unless otherwis note
valu usd unless otherwis note
launch one platform nation gener healthi servic
revenu evoqua host well-attend analyst meet outsid
boston featur busi updat tour showcas tewksburi
manufactur facil outsourc water custom site visit schneider
electr plant much fanfar compani announc readi
nation launch differenti one smart water platform
outsourc water late-summ manag alreadi identifi
mil current revenu potenti opportun one
adopt aim convert ambiti within next three
year addit manag provid help deep-div
capit project revenu gener averag higher-margin
service/aftermarket revenu subsequ year specif gross margin
servic revenu higher initi capit instal given
pressur evoqua face due higher mix capit project
believ new disclosur help clarifi driver
behind compani long-term margin target compani re-affirmed
guidanc framework state aggress roll price
increas potenti reach posit price-cost assum cost
inflat stabil continu posit evoqua highli differenti
posit uniqu water treatment pure-play especi like
busi strateg posit toward higher-end water
forc natur increas pt
palo alto deliv strong quarter outperform metric includ fastest
revenu bill growth sinc rais fy expect
optimist announc new ceo nikesh arora describ us
forc natur enter time strength success combin
cloud-bas background along applic framework could
need know palo alto deliv outstand quarter due healthi
secur spend strong competit win revenu growth
bill growth product growth increas guidanc
compani ad custom tie last quarter second ever
custom increas spend y/i geograph result well
balanc strongest growth apac emea us
impress quarter think addit nikesh arora
equal impress one biggest bear argument palo alto could
left behind cloud-first world given mr arora impress background
googl believ could repres sentiment shift sidelin
share remain under-own rel large-cap growth peer final
concern impli product revenu deceler
believ compani multipl driver includ applic framework
product refresh still early-in
year benefit overal believ palo alto uniqu posit gener
addit drive above-averag growth margin expans scale
maintain op increas target
road manag
valu usd unless otherwis note
encourag new product growth specif compani cloud
agent believ combin new product launch reason
estim better secur spend backdrop help compani maintain
momentum maintain sector perform rais pt peer
need know opportun market manag
like tone meet overal confid manag feel
good current spend environ host new product set
launch year could view reason street revenu growth
expect better backdrop secur
spend commit addit margin expans expect hear
next week analyst day think potenti
maintain momentum look forward next week analyst day
introduct long-term financi target see rais
price target peer group multipl expans
smartsheet held first public earn call report well across board
guid stronger expect growth bill guid particular
impress net retent rate held steadi despit gtm
chang underway rais estim pt maintain outperform
smartsheet report strong first quarter public compani bill revenu
ngoi ebitda ng ep better expect net
retent rate held steadi well estim
report billings/ revenue/ ng oi/ adj ebitda/ ep
y/i y/i vs
new price target end base ev/
valu usd unless otherwis note
recent host investor meet europ ceo kopniski client
focus sever key topic includ client segment increas
product facilit higher revenu expect time magnitud
balanc sheet adjust follow recent acquisit deposit beta
technolog spend
valu usd unless otherwis note
european investor milan geneva amsterdam hear
sterl first time dig subtleti focus profit
deliv consist messag strategi reson client
intent remain dilig remix loan portfolio astoria
lesser degre advantag run-off potenti sale reinvest core
increas core ep estim
respect upward revis expect includ
higher previous forecast net interest margin short-term util
common share repurchas author
arriv price target previous assum multipl
ep tangibl book valu
price target support outperform rate
comp beauti data point depart store nielsen/npd
discount etc seem stabil confid lt market share
opportun howev also believ on-going invest continu
pressur margin next year appreci uniqu
retail superior top bottom line growth vs retail peer believ current
valuat account earn outlook
valu usd unless otherwis note
updat thought estim follow earn
monday present updat result pace-md
trial luspatercept patient md efficaci respons data increment
improv vs decemb updat see note
slight increas iwg hi-e respons transfus independ driven
sever esa-na patent though durat transfus independ
slightli declin iwg hi-e rbc-transfus independ rbc-ti
present includ exhibit page iwg hi-e rbc-ti rate
increas slightli among evalu patient respect
patient baselin epo level iu/l iwg hi-e rbc-ti rate rose
respect vs prior updat new data
report patient baselin epo level iu/l mean durat
treatment rbc-ti respond mo slightli
valu usd unless otherwis note
valu usd unless otherwis note
valu usd unless otherwis note
mo continu evolv overal patient
achiev clinic meaning improv iwg hi-e
patient achiev rbc-ti least week
respons rate slightli higher esa-na patient iwg hi-
 rbc-ti patient overal studi popul
recal on-going medalist studi enrol rs patient
refractori esa base earlier observ luspatercept efficaci
popul
kkr share purchas repres attract use capit impact
take-away view acquisit half kkr stake compani
favor given immedi expect accret approxim
base ep estim believ share purchas like
better lower-risk use cash near term given high valuat
market importantli deal impact strategi
signific revolv expans current work expect deal
announc end summer
takeaway monday saw competitor read-through rubraca
prospect prostat cancer present lynparza zytiga post-
chemo mcrpc well post-hoc analysi data bolster
rubraca posit launch mainten oc competitor lynparza
prostat data mix cautious receiv audience/discuss
though see sever differ today lynparza zytiga combo data vs
post-androgen metastat prostat cancer patient higher unmet
need lower efficaci bar view lynparza limit efficaci
combo safeti result neg read-through trial
separ present post-hoc analys assess impact
variou loh cut-off hrdpo popul impact tumor burden
across differ biomark popul indic rubraca efficaci
benefit meaning experienc regardless stratif view
anoth posit rubraca launch mainten set
potenti enabl rubraca meaning compet popul despit
launch behind competitor zejula tsro lynparza azn
updat investor meet addit detail reward/risk still
compani analyst/investor meet manag expand
mani favor point ph ii melanoma result
continu see reason probabl ad benefit
success ph iii
share reflect littl downsid limit heplisav-b valu
continu see attract invest io space
valu usd unless otherwis note
valu usd unless otherwis note
attend ph ii melanoma data poster
went view updat data favor requir buy-in
concept invers dose relationship dose show
meaning higher respons higher dose someth
acknowledg may discomfort biolog fulli
understood follow analysi ph ii poster discuss
compani believ multipl line evid point potenti
real effect artifact increas confid --
given respons rate arm believ clearli surpass would
expect pembro alon -- good likelihood ph iii success
dose see littl credit share would buyer weak
afternoon present poster updat
data show impress respons lower dose
see plausibl evid lower dose may legitim
perform better biolog reason artifact differ pt
characterist select bia maintain confid
potenti dose
take forward-ii avastin mirv combo appear benefit durat
today report updat result forward-ii cohort
assess mirvetuximab mirv avastin platinum-resist ovarian cancer
proc respons result larg line press releas
though declin slightli vs abstract potenti creat weak
stock specif today poster saw orr
overal popul vs orr abstract subset
patient baselin characterist mirror elig forward-
vs abstract
valu usd unless otherwis note
virginia medicaid expect bring dual benefit lpnt
last week virginia gener assembl approv state budget expand
medicaid coverag approxim low-incom resid state
begin januari well rate increas medicaid provid
estim lpnt see approxim increas ebitda
nearli increas ep expand coverag medicaid rate
enhanc much respect assum
margin expans popul
valu usd unless otherwis note
valu usd unless otherwis note
valu usd unless otherwis note
take cemiplimab cscc data compel competit profil beyond
monday present primari analysi metastat cutan
squamou cell carcinoma cscc cohort trial cemiplimab patient
treat cemiplimab achiev orr durabl dcr
median mo observ respons median dor os yet
reach time data cut-off cemiplimab well toler
common teae diarrhea fatigu nausea common grade
higher teae pneumon anemia diarrhea fatigu constip
result stack favor compar data carskin trial
pembrolizumab metastat cscc show orr dcr
report median mo os yet reach
common teae fatigu rash pain common grade higher
teae relat impair liver function also present
addit result expans cohort trial cemiplimab patient
local advanc metastat cscc result expans cohort
line result present trial patient treat
cemiplimab achiev orr durabl dcr mean
mo respons common teae studi fatigu
common grade hypercalcemia one uti set result
simultan publish nejm
take adcetri continu shine hl sub-group post-hoc
today present sub-group post-hoc analys adcetri
studi hodgkin lymphoma hl focus impact g-csf prophylaxi
pet statu outcom differ adcetri avd vs soc avbd
analys show potenti hl adcetri use usa outperform result
studi appropri incorpor g-csf prophylaxi improv
safeti well efficaci per modifi importantli benefit
seen usa increas vs seen popul
indic adcetri avd could improv patient outcom better real
avd also perform better vs avbd regardless whether patient
petpo petneg see bolster profil post-rathl studi
treatment paradigm view data support high util hl
also present initi result solid tumor studi
immatur data indic patient saw pr await futur
valu usd unless otherwis note
valu usd unless otherwis note
present result prior becom construct asset
remain upsid model
topacio tnbc updat remain confound tsro consid develop
present updat data tripl neg breast cancer tnbc cohort
keytruda zejula combin arm topacio trial
held investor event quadra data addit present earlier
yesterday anticip weak tsro share given topacio
tnbc data deterior slightli vs abstract see note
file strategi may come behind investor estim
tsro investor updat detail increment commerci clinic regulatori
updat tidbit zejula commerci trend posit increment data
tsro april intrinsiq ovarian cancer prescript analysi suggest
domin posit zejula ovarian cancer quadra snda fda submiss
prepar registr combin studi
trso intern own antibodi vs keytruda use topacio
proc tnbc patient popul similar topacio exact
addit complex ad strategi given preliminari safety/
efficaci studi zejula conduct proc tnbc
anticip regulatori disclosur may view somewhat
